Corcept Therapeutics vs Madrigal Pharmaceuticals
CORT and MDGL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CORT and MDGL compare
Madrigal Pharmaceuticals is the larger company, worth 1.3 times as much as Corcept Therapeutics ($9.9B against $7.9B).
Madrigal Pharmaceuticals grew revenue faster over the last twelve months (149% versus 16.0% for Corcept Therapeutics).
Corcept Therapeutics keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with −25.3% at Madrigal Pharmaceuticals.
Corcept Therapeutics scores higher on the StockData Score (11 against 5 for Madrigal Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CORT | MDGL |
|---|---|---|
| Size and price | ||
| Market cap | $7.9B | $9.9B |
| Share price | $72.94 | $427.39 |
| Change, 1 year | −7.0% | −19.2% |
| Change, 5 years | 219% | 419% |
| Beta (5Y) | 0.58 | 0.73 |
| Employees | 730 | 915 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 174× | – |
| P/S | 9.5× | 7.7× (better) |
| P/B | 11.2× (better) | 18.9× |
| EV/EBITDA | 937× | – |
| P/FCF | 73.7× | – |
| FCF yield | 1.4% (better) | −2.1% |
| Fair value | $16.26 | $399.45 |
| Margin of safety | −349% | −7.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.0% | 149% (better) |
| Revenue growth, 5Y average | 16.6% | – |
| Net income growth (TTM) | −58.7% | – |
| EPS growth (TTM) | −62.5% | – |
| EPS growth, 5Y average | −0.72% | – |
| Profitability | ||
| Gross margin | 98.3% | – |
| Operating margin | 0.77% (better) | −25.1% |
| Net margin | 6.6% (better) | −25.3% |
| FCF margin | 12.9% (better) | −16.1% |
| Return on equity | 8.2% (better) | −53.3% |
| Return on invested capital | 1.9% (better) | −1338% |
| Financial health | ||
| Debt / equity | 0.00 | 0.65 (better) |
| Interest coverage | – | −10.2× |
| Current ratio | 2.86 | 3.20 (better) |
| Altman Z-score | 28.24 (better) | 6.67 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | 0.54% | – |
| Shareholder yield | 0.54% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 76.2% | 103% |
| Held by insiders | 14.4% | 27.2% |
| Insider net buying, 12 months | −$93.9M | −$33.3M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.9% | 12.7% |
Go deeper
- CORT stock overview
- CORT income statement
- CORT valuation and score
- MDGL stock overview
- MDGL income statement
- MDGL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.